{"id":136526,"date":"2022-11-11T02:47:50","date_gmt":"2022-11-11T07:47:50","guid":{"rendered":"https:\/\/44.250.171.167\/?p=136526"},"modified":"2022-11-17T09:16:48","modified_gmt":"2022-11-17T14:16:48","slug":"sequent-scientific-limited-q2-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/sequent-scientific-limited-q2-fy23-earnings-conference-call-insights\/","title":{"rendered":"Sequent Scientific Limited Q2 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Sequent Scientific Limited Q2 FY23 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/-5pgj3qU44c?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Sequent Scientific Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/SEQUENT\/\">SEQUENT<\/a>) Q2 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>[00:17:40] Rishab Jain asked about Tineta Pharma acquisition, the products acquired and the synergies SEQUENT is looking at. Rajaram Narayanan MD said that the products largely cover nutritional supplements and some pharmaceutical formulation for the livestock segment. On synergies, SEQUENT has a animal health business specializing in livestock, so combined business will be about INR190 crores.<\/li>\n<\/ul>\n<ul>\n<li>[00:18:24] Rishab Jain also asked about the overall India business outlook over the next 3-4 years. Rajaram Narayanan MD replied that the market is growing 8-10%. SEQUENT\u2019s ambition is to grow much faster than the market.<\/li>\n<\/ul>\n<ul>\n<li>[00:23:45] Vishwas Nandwani enquired about API business, and drivers of decline in revenue in 1H23 of 10% YoY. Rajaram Narayanan MD answered that the drivers were the fire incident and pressure on the demand side. 2H23 is expected to be marginally better than 1H23.<\/li>\n<\/ul>\n<ul>\n<li>[00:24:35] Vishwas Nandwani asked about new products and if the margin profile of these products are better than existing business margins. Rajaram Narayanan MD answered that margins of new products would be typically lower initially for few quarters and then improve rapidly. Therefore, overall SEQUENT expects sustainable margins without any currency impact.<\/li>\n<\/ul>\n<ul>\n<li>[00:30:20] Nikunj Jain with NJ Investments asked about the reason for weakening of the Europe business and when it will recover. Rajaram Narayanan MD replied that it\u2019s due to economic conditions related to war and increase in fertilizer price that resulted in reduction in demand at farmer level. In 4-6 quarters SEQUENT should see topline growth coming back if the economic situation improves.<\/li>\n<\/ul>\n<ul>\n<li>[00:37:16] Bhavya Shah of Girik Capital asked about the GM decline of 100 bps in 2Q23 and if the company expects any further declines. P. V. Raghavendra Rao CFO answered that from a business perspective GM is stable. And due to hyperinflationary accounting, SEQUENT had to take some hit on GM of 1.1%. Removing that, GM is stable.<\/li>\n<\/ul>\n<ul>\n<li>[00:39:13] Vishal from Systematix enquired if the $10 million API supply order is commercialized from a global top 10 company. Rajaram Narayanan MD said that the $10 million has not yet materialized but the start of the supplies has materialized.<\/li>\n<\/ul>\n<ul>\n<li>[00:43:25] Vishal of Systematix asked if there is an incremental change in regulation in terms of usage of antibiotics or these are just old regulations. Rajaram Narayanan MD clarified that the regulations are more than three years old, but it has been staggered in the implementation.<\/li>\n<\/ul>\n<ul>\n<li>\u00a0[00:45:37] Udit Bokaria with Catamaran enquired about Albendazole sales in the API and the peak numbers two, three years ago. Rajaram Narayanan MD answered that the Albendazole business about 3 years ago, used to be in about 15% odd of total business. And today it is down to less than 10%.<\/li>\n<\/ul>\n<ul>\n<li>[00:47:24] Anand Trivedi of Nepean Capital asked that given the cost pressure in Europe, if there is an opportunity to move some of the manufacturing to India and benefit from lower cost. Rajaram Narayanan MD replied that in Europe SEQUENT is serving local markets from a manufacturing location there. So it\u2019s not a distinctive advantage to shift it to India.<\/li>\n<\/ul>\n<ul>\n<li>[00:48:45] Anand Trivedi of Nepean Capital also enquired that with the stress in European markets, if there is any M&amp;A opportunities opening up in Europe. Rajaram Narayanan MD said that from a full-fledged acquisition point, SEQUENT is open to it. But currently the company is not ready for anything.<\/li>\n<\/ul>\n<ul>\n<li>[00:55:34] Aditya Khemka from InCred asked about acquisition and how SEQUENT is going to fund the cash consideration. Rajaram Narayanan MD replied that it\u2019s a combination of issue of preferential equity already declared, internal cash generation and some restructuring of intercompany financing.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Sequent Scientific Limited (SEQUENT) Q2 FY23 Earnings Concall Q&amp;A Highlights: [00:17:40] Rishab Jain asked about Tineta Pharma acquisition, the products acquired and the synergies SEQUENT is looking at. Rajaram Narayanan MD said that the products largely cover nutritional supplements and some pharmaceutical formulation for the livestock segment. On synergies, SEQUENT has a [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Sequent Scientific Limited Q2 FY23 Earnings Conference Call Insights #SEQUENT #Q2 #FY23 #Earnings #Stocks","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[10169,8157,1115],"class_list":["post-136526","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-earnings","tag-healthcare","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":143225,"url":"https:\/\/alphastreet.com\/india\/sequent-scientific-limited-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":136526,"position":0},"title":"Sequent Scientific Limited Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"March 9, 2023","format":false,"excerpt":"Key highlights from Sequent Scientific Limited (SEQUENT) Q3 FY23 Earnings Concall Management Update: [00:05:37] SEQUENT said that in the API business, the company crossed the INR100 crore revenue mark in 3Q23, with a 16.5% sequential quarter-on-quarter growth. Q&A Highlights: [00:17:59] Rahul Maheshwari enquired about the growth rate targeted for Europe\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":147273,"url":"https:\/\/alphastreet.com\/india\/sequent-scientific-limited-q4-fy23-earnings-conference-call-insights\/","url_meta":{"origin":136526,"position":1},"title":"Sequent Scientific Limited Q4 FY23 Earnings Conference Call Insights","author":"Praveen","date":"May 25, 2023","format":false,"excerpt":"Key highlights from Sequent Scientific Limited (SEQUENT) Q4 FY23 Earnings Concall Q&A Highlights: [00:14:02] Vishwas asked about the utilization of the API plant, plans for adding more capacity, products in the pipeline, and potential revenue from new APIs. Rajaram Narayanan MD replied that current utilization is 70-75% and SEQUENT plans\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":137387,"url":"https:\/\/alphastreet.com\/india\/sequent-scientific-limited-sequent-q2-fy23-earnings-concall-transcript\/","url_meta":{"origin":136526,"position":2},"title":"Sequent Scientific Limited (SEQUENT) Q2 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"November 8, 2022","format":false,"excerpt":"Sequent Scientific Limited (NSE:SEQUENT) Q2 FY23 Earnings Concall dated Nov. 08, 2022 Corporate Participants: Abhishek Singhal -- Head of Investor Relations Rajaram Narayanan -- Managing Director P. V. Raghavendra Rao -- Chief Financial Officer Sharat Narasapur -- Joint Managing Director Analysts: Rishab Jain -- Individual Investor -- Analyst Vishwas Nandwani\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"stock earnings conference call transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":127593,"url":"https:\/\/alphastreet.com\/india\/sequent-scientific-limited-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":136526,"position":3},"title":"Sequent Scientific Limited Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 15, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=iqM668J91yY Key highlights from Sequent Scientific Limited (SEQUENT) Q3 FY22 Earnings Concall Management Update: SEQUENT saw significant improvement in the API order book and dispatches in the quarter that were almost at 3Q21 levels, which was the best ever quarter in terms of the reported API numbers. Q&A Highlights: Sanam\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":175161,"url":"https:\/\/alphastreet.com\/india\/sequent-scientific-limited-sequent-q1-2026-earnings-call-transcript\/","url_meta":{"origin":136526,"position":4},"title":"Sequent Scientific Limited (SEQUENT) Q1 2026 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Sequent Scientific Limited (NSE: SEQUENT) Q1 2026 Earnings Call dated Aug. 11, 2025 Corporate Participants: Unidentified Speaker Abhishek Singhal \u2014 Head of Investor Relations Rajaram Narayanan \u2014 Managing Director Saurav Bhala \u2014 Chief Financial Officer Hari Babu Bodepudi \u2014 Non-Executive Director Analysts: Unidentified Participant Shiwani Kumari \u2014 Analyst Vishal Manchanda\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":175165,"url":"https:\/\/alphastreet.com\/india\/sequent-scientific-limited-sequent-q2-2025-earnings-call-transcript\/","url_meta":{"origin":136526,"position":5},"title":"Sequent Scientific Limited (SEQUENT) Q2 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Sequent Scientific Limited (NSE: SEQUENT) Q2 2025 Earnings Call dated Nov. 14, 2024 Corporate Participants: Abhishek Singhal \u2014 Head of Investor Relations Rajaram Narayanan \u2014 Managing Director Saurav Bhala \u2014 Chief Financial Officer Hari Babu \u2014 Whole Time Director and CEO Analysts: Hrithika \u2014 Analyst Nikhil Shetty \u2014 Analyst Bharat\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/136526","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=136526"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/136526\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=136526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=136526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=136526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}